BMC Infectious Diseases (Feb 2022)

Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report

  • Xiao Lin,
  • Aixin Song,
  • Sujun Zheng,
  • Xinyue Chen

DOI
https://doi.org/10.1186/s12879-022-07159-y
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background Mitochondrial myopathy caused by the long-term use of nucleos(t)ide analogue in patients with chronic hepatitis B (CHB) is mostly characterized by myasthenia and myalgia. Cases with respiratory failure as the prominent manifestation and multisystem symptoms have not been reported. Case report We report a case of mitochondrial myopathy associated with the long-term use of entecavir for CHB. The patient was a 54-year-old male who was treated with entecavir for 9 years. During the treatment, hepatitis B virus (HBV) DNA was negative and liver function was normal. However, generalized fatigue, poor appetite, dysosmia and other discomforts gradually presented starting at the 5th year of treatment, and respiratory failure was the prominent manifestation in the later stage of disease progression. The diagnosis was based on histopathology examination. The dysosmia, hypoxemia and digestive tract symptoms were gradually improved after withdrawal of entecavir. Discussion Mitochondrial myopathy is a rare side effect of entecavir and can be diagnosed by muscle biopsy. Although the incidence is extremely low, but the severe cases can lead to respiratory failure. We should receive adequate attention in clinical practice.

Keywords